Perimenstrual catamenial epilepsy

Women's Health

Volumn 3, Issue 2, 2007, Pages 195-206

  Reddy, Doodipala Samba ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

aminobutyric acid A receptor; Epilepsy; Ganaxolone; Menstrual cycle; Neurosteroid; Progesterone

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ACETAZOLAMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ESTROGEN; ETHOSUXIMIDE; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; GANAXOLONE; LAMOTRIGINE; MEDROXYPROGESTERONE ACETATE; MESUXIMIDE; NEUROSTEROID; NITRAZEPAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ASTHENIA; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CATAMENIAL EPILEPSY; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE MODEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG WITHDRAWAL; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MEDICAL ASSESSMENT; MEDICAL RECORD; MENSTRUAL CYCLE; MENSTRUATION; NONHUMAN; OVULATION; PATHOPHYSIOLOGY; PATIENT CARE; REVIEW; SEDATION; SIDE EFFECT; SPOTTING; WEIGHT GAIN;

EID: 33947621030     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.2.195     Document Type: Review

References (52)

1. Rogawski MA: Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 68, 22-28 (2006).
2. Herzog AG: Menstrual disorders in women with epilepsy. Neurology 66(6 Suppl. 3), S23-S28 (2006).
3. Rosciszewska D: Analysis of seizure dispersion during mentrual cycle in women with epilepsy. Monogr. Neural Sci. 5, 280-284 (1980).
4. Tauboll E, Lundervold A, Gjerstad L: Temporal distribution of seizures in epilepsy. Epilepsy Res. 8, 153-165 (1991).
5. Duncan S, Read CL, Brodie MJ: How common is catamenial epilepsy? Epilepsia 34, 827-831 (1993).
6. Towanabut S, Chulavatnatol S, Suthisisang C, Wanakamanee U: The period prevalence of catamenial epilepsy at Prasat Neurological Institute, Bangkok. J. Med. Assoc. Thai. 81, 970-977 (1998).
7. Herzog AG, Harden CL, Liporace J et al.: Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann. Neurol. 56, 431-434 (2004).
8. Bazan AC, Montenegro MA, Cendes F, Min LL, Guerreiro CA: Menstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsy. Arg. Neuropsiquiatr. 63(3B), 751-756 (2005).
9. Newmark ME, Penry JK: Catamenial epilepsy: a review. Epilepsia 21, 281-300 (1980).
10. Reddy DS: Pharmacology of catamenial epilepsy. Methods Find. Exp. Clin. Pharmacol. 26, 547-561 (2004).
11. Herzog AG, Klein P, Ransil BJ: Three patterns of catamenial epilepsy. Epilepsia 38, 1082-1088 (1997).
12. Foldvary-Schaefer N, Falcone T: Catamenial epilepsy: pathophysiology, diagnosis, and management. Neurology 61 (Suppl. 2), S2-S15 (2003).
13. Reddy DS: Role of neurosteroids in catamenial epilepsy. Epilepsy Res. 62, 99-118 (2004).
14. Morrell MJ, Montouris GD: Reproductive disturbances in patients with epilepsy. Cleve. Clin. J. Med. 71(Suppl. 2), S19-S24 (2004).
15. Bilo L, Meo R: Epilepsy and polycystic ovary syndrome: where is the link? Neurol. Sci. 27, 221-230 (2006).
16. Rogawski MA, Loescher W: The neurobiology of antiepileptic drugs. Nature Rev. Neurosci. 5, 553-564 (2004).
17. Isojarvi JI, Tauboll E, Herzog AG: Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drug 19, 207-223 (2005).
18. Buterbaugh GG: Estradiol replacement facilitates the acquisition of seizures kindled from the anterior neocortex in female rats. Epilepsy Res. 4, 207-215 (1989)
19. Bonuccelli U, Melis GB, Paoletti AM, Fioretti P, Murri L, Muratorio A: Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res. 3, 100-106 (1989).
20. Logothetis J, Harner R, Morrel F: The role of estrogens in catamenial exacerbation of epilepsy. Neurology 9, 352-360 (1959).
21. Weiland NG: Glutamic acid decarboxylase messenger ribonucleic acid is regulated by estradiol and progesterone in the hippocampus. Endocrinology 131, 2697-2702 (1992).
22. Nakamura NH, Roseu DR, Akama KT, McEwen BS: Estrogen and ovariectomy regulate mRNA and protein of glutamic acid decarboxylases and cation-chloride cotransporters in the adult rat hippocampus. Neuroendocrinology 80, 308-323 (2004).
23. Joh HD, Searles RV, Selmanoff M et al.: Estradiol alters only GAD67 mRNA levels in ischemic rat brain with no consequent effects on GABA. J. Cereb. Blood Flow Metab. 26, 518-526 (2006).
24. Reddy DS, Castenada DA, O'Malley BW, Rogawski MA: Antiseizure activity of progesterone and neurosteroids in progesterone receptor knockout mice. J. Pharmacol. Exp. Ther. 310, 230-239 (2004).
25. Lonsdale D, Burnham WM: The anticonvulsant effects of progesterone and 5α-dihydroprogesterone on amygdalakindled seizures in rats. Epilepsia 44, 1494-1499 (2003).
26. Wang M, Seippel J., Purdy RH, Bäckström T: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J. Clin. Endocrinol. Metab. 81, 1076-1082 (1996).
27. Reddy DS: Pharmacology of endogenous neuroactive steroids. Crit. Rev. Neurobiol. 15, 197-234 (2003).
28. A receptors. Prog. Neurobiol. 71, 67-80 (2003).
29. A receptor α4-suburilt suppression prevents withdrawal properties of an endogenous steroid. Nature 392, 926-930 (1998).
30. Laidlaw J: Catamenial epilepsy. Lancet 271. 1235-1237 (1956).
31. Reddy DS, Kim Y-H, Rogawski MA: Neurosteroid withdrawal model of perimenstrual catamenial epilepsy Epilepsia 42, 328-336 (2001).
32. Reddy DS, Rogawski MA: Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J. Pharmacol. Exp. Themp. 294, 909-915 (2000).
33. Herzog AG: Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 52, 1917-1918 (1999).
34. Zimmerman AW, Holder DT, Reiter EO, Dekaban AS: Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J. Pediatr. 83, 959-963 (1973).
35. Ansell B, Clarke E: Acetazolamide in treatment of epilepsy. BMJ 1, 650-661 (1956).
36. Ross IP: Acetazolamide therapy in epilepsy. Lancet 2, 1308-1309 (1958).
37. Lim LL, Foldvary N, Mascha E, Lee J: Acetazolamide in women with catamenial epilepsy. Epilepsia 42, 746-749 (2001).
38. Haigh JRM, Feely M: Tolerance to the anticonvulsant effect of benzodiazepines. Tiends Pharmacol. Sci. 9, 361-366 (1988).
39. Feely M, Calvert R, Gibson J: Clobazam in catamenial epilepsy: a model for evaluating anticonvulsants. Lancet 2, 71-73 (1982).
40. Feely M, Gibson J: Intermittent clobazam for catamenial epilepsy: tolerance avoided. J. Neurol. Neursurg. Psychiatry 47. 1279-1282 (1984).
41. Reddy DS, Rogawski MA: Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 295, 1241-1248 (2000).
42. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC: Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 34, 1255-1258 (1984).
43. Herzog AG: Intermittent progesterone therapy of partial complex seizures in women with menstrual disorders. Neurology 36, 1607-1610 (1986).
44. Herzog AG: Progesterone theraphy in women with complex partial and secondary generalized seizures. Neurology 45, 1600-1662 (1995).
45. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA: Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J. Pharmacol. Exp. Ther. 288, 679-684 (1999).
46. Frye CA, Rhodes ME, Walf A, Harney J: Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5α-reductase. Epilepsia 43 (Suppl. 5), 14-17 (2002).
47. Herzog AG, Frye CA: Seizure exacerbation associated with inhibition of progesterone metabolism. Ann. Neurol. 53, 390-391 (2003).
48. Reddy DS, Rogawski MA: Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 42, 303-310 (2001).
49. Reddy DS, Woodward R: Ganaxolone: a prospective overview. Drugs Future 29, 227-242 (2004).
50. Monaghan EP, Navalta LA, Shum L, Ashbrock DW, Lee DA: Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 38, 1026-1031 (1997).
51. McAuley JW, Moore JL, Reeves AL, Flyak J, Monaghan EP, Data J: A pilot study of the neurosteroid ganaxolone in catamenial epilepsy: clinical experience in two patients. Epilepsia 42, 85-85 (2001).
52. Crawford P: Best practice guidelines for the management of women with epilepsy. Epilepsia 46(Suppl. 9), 117-124 (2005).